Novo Nordisk CEO on medicare coverage, new obesity pill, U.S. pricing pressure

Novo Nordisk CEO Mike Doustdar Interview Summary

Key Concepts:

• Wegovy Pill: Novo Nordisk’s oral semaglutide medication for weight loss.
• GLP-1 Receptor Agonists: Class of drugs used for treating type 2 diabetes and obesity, stimulating insulin release and suppressing appetite. (e.g., semaglutide, tirzepatide)
• Pricing Headwinds: Negative impact on revenue due to price reductions and payer negotiations.
• Market Share: Proportion of total sales captured by a company within a specific market.
• Cagrisema: Novo Nordisk’s investigational combination of GLP-1 and amylin receptor agonists.
• Compounding Pharmacies: Facilities that customize medications, often involved in recent shortages of GLP-1s.
• Medicare Coverage: Potential expansion of access to obesity drugs through the Medicare program.
• Amylin: A hormone co-secreted with insulin that helps regulate appetite and glucose control.
• NBR (New to Brand Prescriptions): Number of new prescriptions written for a specific brand.

I. 2026 Outlook & Wegovy Pill Launch

Novo Nordisk anticipates a negative sales growth in 2026 due to pricing pressures, but emphasizes this year will also see record patient numbers, increased production, and pipeline growth. The launch of the Wegovy pill has been exceptionally successful, with 246,000 people currently prescribed it within five weeks of launch. The company believes that initial investor concerns regarding pricing will be mitigated by increasing volume and future product developments. Doustdar stated, “We have, for a while now has been speaking at 2026 will be a different year… it’s also a year of growth in many ways.”

II. Driving Momentum: Volume, Medicare & Pill Adoption

Momentum will be driven by a combination of factors. Expanding access through channels like Medicare is crucial, opening potential access to 67 million people. The pill format is a significant driver, appealing to individuals hesitant about injections due to needle phobia or social stigma. Novo Nordisk is actively working to demonstrate the efficacy of Wegovy compared to competitors, highlighting that the current 2.4mg dose achieves around 15-16% weight loss, while competitors’ 15mg dose yields 20-21% weight loss. A higher dose of Wegovy is being introduced to address this efficacy gap. Doustdar noted, “Now all of a sudden they don't need to wait. They can take a daily pill and get a very similar efficacy as to the injectable products that we have out there.”

III. Wegovy Pill Launch Takeaways & Supply Chain

Key takeaways from the Wegovy pill launch include the importance of a strong launch campaign (including high-profile advertising like during the Super Bowl) and effectively communicating the pill’s efficacy. Novo Nordisk is emphasizing that the pill’s peptide formulation, encapsulated in special technology, delivers comparable efficacy to injectable versions. A key learning is “meet the patients where they are,” partnering with various channels like Weight Watchers and Amazon Pharmacy to maximize access. Maintaining supply is a top priority, learning from past shortages that led to the rise of compounding pharmacies. Doustdar emphasized, “We have said to ourselves, never again on a shortage.” The company has filed for registration and approval in the European Union, indicating confidence in expanding beyond the US market.

IV. Competitive Landscape & Efficacy

Novo Nordisk acknowledges that patient perception often favors higher doses, even if the clinical benefit isn’t proportionally greater. The company is actively working to demonstrate the efficacy of its products, particularly the higher-dose Wegovy, and highlight additional benefits like cardiovascular and liver protection. Clinical trial data shows the Wegovy pill achieves 16.6% weight loss compared to a competitor’s pill at 12.4%. Doustdar stated, “If you take these two numbers, basically you have a 40% four, 0% difference between the efficacy of these pills.” Gastrointestinal tolerability is also a key differentiator, with Wegovy showing a lower discontinuation rate (3.6%) compared to a competitor (10.4%).

V. Addressing Compounding Pharmacies & Legal Action

Novo Nordisk is actively combating the proliferation of compounded semaglutide products, even after the initial supply shortages have been resolved. The company has filed over 120 lawsuits and recently sued Hims & Hers, citing concerns about patient safety due to unregulated raw materials sourced from potentially unsafe origins (often China) bypassing FDA oversight. Doustdar emphasized the importance of protecting intellectual property and ensuring continued innovation. He stated, “Our industry lives and dies from intellectual property… if someone can completely ignore and bypass the system… it really puts a question mark how much innovation will come tomorrow.” The company welcomes the support from the DOJ and FDA and hopes for a more aggressive approach to regulating compounding pharmacies.

VI. Medicare Coverage & Volume Expectations

Novo Nordisk anticipates a gradual rollout of Medicare coverage, targeting approximately 15 million patients initially. While the potential market is large (67 million Medicare beneficiaries), access will likely be phased, mirroring challenges seen with commercial insurance plans (55 million insured, but only a few million with access). The company is engaging in ongoing negotiations with Medicare plans to ensure meaningful access and align with pricing.

VII. Pipeline Strategy: Alzheimer’s & Cagrisema

Novo Nordisk is re-evaluating its Alzheimer’s strategy following a Phase 3 trial failure, despite positive biomarker results and patient testimonials. While the potential benefits of GLP-1 on brain health are acknowledged, no immediate plans for further investigation are in place. Cagrisema, a combination GLP-1 and amylin receptor agonist, is considered a potentially groundbreaking product, with the potential to be the first amylin-based treatment on the market. Clinical trials (redefine one, four, and eleven) are designed to assess efficacy at various doses, recognizing that higher doses generally correlate with greater weight loss. Doustdar stated, “If Cagrisema was available today in a pharmacy… it would be one of the best products out there.”

VIII. Market Share & Future Strategy

Novo Nordisk currently holds approximately 40% market share, compared to Lilly’s 60%. While Wegovy has the highest number of new-to-brand prescriptions, the company acknowledges the need to address the preference share, where a majority of patients initially choose competitors’ products. The strategy focuses on demonstrating the efficacy of higher-dose Wegovy, highlighting its additional benefits (cardio, liver, kidney protection), and emphasizing the comparable efficacy to competitors. Doustdar believes that a shift in perception will drive market share gains.

IX. Diversification & Future Outlook

Novo Nordisk does not see a need to significantly diversify its pipeline beyond obesity and diabetes, viewing these conditions as a spectrum with diverse patient needs. The company is developing targeted treatments for different obesity phenotypes, recognizing that a patient needing to lose a few kilos is distinct from someone with severe obesity and associated complications.

Conclusion:

Novo Nordisk is navigating a complex landscape of pricing pressures, competitive challenges, and supply chain considerations. The successful launch of the Wegovy pill is a key driver of growth, but the company is focused on expanding access through Medicare, demonstrating efficacy, combating compounding pharmacies, and advancing its pipeline with innovative treatments like Cagrisema. The company’s strategy centers on addressing unmet patient needs and solidifying its position as a leader in the obesity and diabetes treatment space.